Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a significant drop in short interest during the month of January. As of January 30th, there was short interest totaling 215,761 shares, a drop of 14.7% from the January 15th total of 253,018 shares. Approximately 1.3% of the company’s stock are sold short. Based on an average daily volume of 129,627 shares, the short-interest ratio is currently 1.7 days. Based on an average daily volume of 129,627 shares, the short-interest ratio is currently 1.7 days. Approximately 1.3% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

ALLR has been the topic of several recent research reports. Ascendiant Capital Markets raised their price objective on shares of Allarity Therapeutics from $9.25 to $9.50 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Allarity Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $9.50.

Allarity Therapeutics Price Performance

Shares of ALLR opened at $0.85 on Tuesday. The company has a market capitalization of $13.59 million, a PE ratio of -1.43 and a beta of 0.23. Allarity Therapeutics has a one year low of $0.61 and a one year high of $2.35. The company’s fifty day moving average price is $1.06 and its 200 day moving average price is $1.25.

Allarity Therapeutics (NASDAQ:ALLR) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. Analysts anticipate that Allarity Therapeutics will post -78.08 earnings per share for the current year.

Institutional Trading of Allarity Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. DRW Securities LLC bought a new position in Allarity Therapeutics in the fourth quarter worth $133,000. Renaissance Technologies LLC lifted its holdings in shares of Allarity Therapeutics by 274.1% during the 4th quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after acquiring an additional 181,426 shares during the period. Citadel Advisors LLC bought a new position in shares of Allarity Therapeutics during the 3rd quarter worth about $149,000. Private Advisor Group LLC acquired a new stake in shares of Allarity Therapeutics during the 3rd quarter valued at about $441,000. Finally, XTX Topco Ltd bought a new stake in Allarity Therapeutics in the second quarter valued at about $51,000. Institutional investors and hedge funds own 11.53% of the company’s stock.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.